Vera Cvoro

Vera Cvoro

Auto-generated profile, based on publicly available information

Vera Cvoro

Centre for Clinical Brain Sciences and UK Dementia Research Institute, University of Edinburgh

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Neurology
Verified
Journal Article
Open access
PDF file
UCUna Clancy
Una Clancy
SMStephen D.J. Makin
Stephen D.J. Makin
CMCaroline McHutchison
Caroline McHutchison
VCVera Cvoro
Vera Cvoro
FCFrancesca Chappell
Francesca Chappell
JWJoanna M Wardlaw
Joanna M Wardlaw
Background and Objectives The severity of white matter hyperintensities (WMH) at presentation with stroke is associated with poststroke dementia and dependency. However, WMH can decrease or increase after stroke; prediction of cognitive decline is imprecise; and there are few data assessing longitudinal interrelationships among changing WMH, cognition, and function after stroke, despite the clinical importance. Methods We recruited patients within 3 months of a minor ischemic stroke, defined as NIH Stroke Scale (NIHSS) score 2. Participants repeated MRI at 1 year and cognitive and mRS assessments at 1 and 3 years. We ran longitudinal mixed-effects models assessing change in Addenbrooke’s Cognitive Examination–Revised (ACE-R) and mRS scores. For mRS score, we assessed longitudinal WMH volumes (cube root; percentage intracranial volume [ICV]), adjusting for age, NIHSS score, ACE-R, stroke subtype, and time to assessment. For ACE-R score, we additionally adjusted for ICV, mRS, premorbid IQ, and vascular risk factors. We then used a multivariate model to jointly assess changing cognition/mRS score, adjusted for prognostic variables, using all available data. Results We recruited 264 patients; mean age was 66.9 (SD 11.8) years; 41.7% were female; and median mRS score was 1 (interquartile range 1–2). One year after stroke, normalized WMH volumes were associated more strongly with 1-year ACE-R score (β = −0.259, 95% CI −0.407 to −0.111 more WMH per 1-point ACE-R decrease, p = 0.001) compared to subacute WMH volumes and ACE-R score (β = 0.105, 95% CI −0.265 to 0.054, p = 0.195). Three-year mRS score was associated with 3-year ACE-R score (β = −0.272, 95% CI −0.429 to −0.115, p = 0.001). Combined change in baseline-1-year jointly assessed ACE-R/mRS scores was associated with fluctuating WMH volumes (F = 9.3, p = 0.03). Discussion After stroke, fluctuating WMH mean that 1-year, but not baseline, WMH volumes are associated strongly with contemporaneous cognitive scores. Covarying longitudinal decline in cognition and independence after stroke, central to dementia diagnosis, is associated with increasing WMH volumes.

9 September 2025 in Neurology
Verified
Journal Article
Open access
DGDaniela Jaime Garcia
Daniela Jaime Garcia
SMStephen D.J. Makin
Stephen D.J. Makin
CMCaroline McHutchison
Caroline McHutchison
VCVera Cvoro
Vera Cvoro
MHMaria Del C. Valdés Hernández
Maria Del C. Valdés Hernández
JWJoanna M Wardlaw
Joanna M Wardlaw
Data on outcomes after minor stroke, especially lacunar stroke, are lacking or based on short follow-up. Outcome differences between lacunar and cortical stroke remain unclear but may provide insights into small vessel disease (SVD) etiology and prognosis. We report on dementia, death, recurrent stroke, and function up to 9 years after lacunar or minor cortical ischemic stroke. In this 9-year longitudinal observational cohort study, we prospectively recruited participants presenting with mild, nondisabling lacunar or cortical ischemic stroke to Lothian Stroke Services in Edinburgh, United Kingdom. At baseline, we collected data on sociodemographics, vascular risk factors, dependence, cognition, and brain MRI. At 9 years, we used questionnaires (including items from the Stroke Impact Scale) and hospital/general practitioner records to assess dementia, recurrent stroke, death, cardiac diseases, vascular risk factors, dependence, recovery, and functionality. We recruited 264 participants; clinical data were available for 243 participants (92%) (baseline mean age 67 years (SD 12), 42% female, 44% with lacunar stroke) and self-reported functional data for 96 (36%) at a mean follow-up of 8.5 years (SD 0.57). Dementia was diagnosed in 9.4% of participants with lacunar stroke and 12.4% of those with cortical stroke, with risk increasing with age (odds ratio [OR] 1.08; CI 1.030-1.130). Recurrent stroke occurred in one-third of all participants; risk increased with the presence of vascular risk factors (OR 2.27; CI 1.287-4.032). Participants with cortical stroke were more likely to die compared with those with lacunar stroke (χ2 = 8.2; p = 0.004). Age (OR 1.09; CI 1.051-1.133), male sex (female OR 0.40, CI 0.196-0.818), and white matter hyperintensities (OR 1.36; CI 1.112-1.664) increased risk of death. Moderate/severe disability was reported by 12% of participants and cognitive concerns by 49%-55%. Affected limb recovery and balance were worse after lacunar stroke (W = 705.5, p = 0.00). Long-term outcomes after minor stroke were frequently suboptimal and varied by stroke subtype, highlighting the lasting impact of both lacunar and mild cortical ischemic strokes on quality of life. Improving long-term outcomes after mild stroke remains an important target for refining clinical care and shaping future research directions.

1 April 2021 in Health Services and Delivery Research
Verified
Journal Article
Closed access
EREmma Reynish
Emma Reynish
SHSimona Hapca
Simona Hapca
RWRebecca Walesby
Rebecca Walesby
APAngela Pusram
Angela Pusram
FBFeifei Bu
Feifei Bu
BGBruce Guthrie
Bruce Guthrie
Health Services and Delivery Research Volume: 9, Issue: 8, Published in April 2021

30 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
TZThomas Zhang
Thomas Zhang
UCUna Clancy
Una Clancy
ASAyush Singh
Ayush Singh
SMStephen Makin
Stephen Makin
CMCaroline McHutchison
Caroline McHutchison
JWJoanna M Wardlaw
Joanna M Wardlaw
Background: Novel risk factors for stroke, such as occupation, are increasingly under exploration. We investigate if specific occupational exposures and settings increase the risk of developing small‐vessel disease (SVD), including SVD‐related strokes. Methods: We performed a systematic review on stroke–occupation associations and then analyzed data from patients presenting to Lothian stroke services with mild ischemic stroke (modified Rankin Scale score ≤2). We performed magnetic resonance imaging and inquired about occupational status. We assessed relationships between high‐risk occupations (per Control to Substances Hazardous to Health guidelines) and standard occupational classifications (per Standard Occupational Classifications criteria) against white matter hyperintensity volumes, SVD score, and stroke subtype. Results: Our systematic review identified 37 papers assessing occupations/broad occupational classifications (n=13), psychosocial work‐related factors (n=11), and occupational exposure to hazardous substances (n=13). We then analyzed data from 414 participants and found, after adjustment for age, hypercholesterolemia, socioeconomic status, years of education, hypertension, diabetes, and smoking history, that high‐risk occupations were associated with higher SVD scores (odds ratio, 1.64 [95% CI, 1.07–2.54]; n=357; P =0.02) but not for lacunar stroke subtype (odds ratio, 1.03 [95% CI, 0.64–1.67]; n=358; P =0.90) or white matter hyperintensity volume (% intracranial volume) (β=−0.003 [95% CI, −0.015 to 0.008]; n=357; P =0.60). Examples of high‐risk occupations include drivers, engineers, and skilled trade workers. No associations were found for standard occupational classifications. Conclusions: This systematic review shows limited data on stroke–occupation associations. Our analysis showed that high‐risk occupations are associated with higher SVD scores but not stroke subtype. Registration: URL: www.crd.york.ac.uk/PROSPERO ; Unique Identifier: 42024466671.

6 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
PBPhilip M. Bath
Philip M. Bath
LILACI-2 Trial Investigators
LACI-2 Trial Investigators
LWLisa J Woodhouse
Lisa J Woodhouse
IMIris Mhlanga
Iris Mhlanga
JBJohn M Bamford
John M Bamford
JWJoanna M Wardlaw
Joanna M Wardlaw
Background: Lacunar stroke, a type of cerebral small vessel disease (cSVD), causes cognitive decline and dependency. The LACunar Intervention Trial-2 (LACI-2) trial showed that 12 months of treatment with isosorbide-mononitrate (ISMN) and/or cilostazol improved these outcomes. We tested whether this effect was present at 6 months, a pre-specified analysis. Methods: LACI-2 assessed the feasibility, safety and proof-of-concept of one year of ISMN (40-60mg) and/or cilostazol (200 mg) using a prospective randomised open-label blinded-endpoint 2×2-factorial phase-2b design. Participants aged>30yrs had clinical lacunar stroke, compatible brain imaging and capacity to consent. Key outcomes included cognition (Diagnostic and Statistical Manual version 5-7-level, DSM5-7L), dependency, vascular events, mood, stroke impact and a global analysis of these. Results: Baseline characteristics were balanced across 363 participants: median age 64 [56-72] years, females 31% and median onset-to-randomisation 79 [27-244] days. At 6 months, participants allocated to ISMN vs control had fewer vascular-cognition-dependency events (adjusted odds ratio, aOR 0.74, 95% confidence intervals 0.55-0.99) and an improved stroke impact scale score (Mann-Whitney difference, MWD - 0.15, 95% CI −0.25, −0.05) and global analysis (MWD −0.06, 95% CI −0.11, −0.01). Cilostazol vs control reduced cognitive impairment (DSM5-7-level scale, acOR 0.64, 95% CI 0.41-0.99). Combined ISMN/cilostazol vs control (n=181) had improved cognition (DSM5-7L acOR 0.40, 95% CI 0.21-0.78) and mood (Zung aMD −6.94, 95% CI −12.25, −1.64), reduced stroke impact (−0.23, 95% CI −0.37, −0.09) and a better global outcome (MWD −0.10, 95% CI −0.17, −0.03). Conclusions: Improvements in cognitive and functional outcomes were seen within 6 months of ISMN and/or cilostazol. Registration: ISRCTN14911850 : https://www.isrctn.com/ISRCTN14911850

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
PBPhilip M. Bath
Philip M. Bath
LWLisa J. Woodhouse
Lisa J. Woodhouse
IMIris Mhlanga
Iris Mhlanga
JBJohn Bamford
John Bamford
VCVera Cvoro
Vera Cvoro
JWJoanna M Wardlaw
Joanna M Wardlaw
Background: Lacunar stroke can cause cognitive decline and dependency. The LACI‐2 (Lacunar Intervention Trial‐2) trial showed that 12 months of treatment with isosorbide‐mononitrate (ISMN) or cilostazol improved these outcomes. We tested whether this effect was present at 6 months. Methods: LACI‐2 was a prospective randomized open‐label blinded‐end point 2×2‐factorial phase‐2b trial assessing feasibility, safety, and proof‐of‐concept of 1 year of ISMN (40–60 mg) or cilostazol (200 mg). Participants aged >30 years had clinical lacunar stroke, compatible neuroimaging, and capacity to consent. The primary clinical outcome was the composite of stroke, myocardial infarction, dependency (modified Rankin Scale score >2), cognitive impairment ( Diagnostic and Statistical Manual version 5, 7‐level >0) and death; key secondary outcomes included the composite components, mood and stroke impact scale. Global analysis of the stroke impact scale was analyzed using the Wei–Lachin test with result given as Mann–Whitney difference. Results: Baseline characteristics were balanced across 363 participants: median age 64 (56–72) years, 31% female, and median onset to randomization 79 (27–244) days. At 6 months, participants allocated to ISMN versus control had fewer composite events (adjusted odds ratio [OR], 0.74 [95% CI, 0.55–0.99]) and improved stroke impact (Mann–Whitney difference, −0.15 [95% CI −0.25 to −0.05]). Cilostazol versus control improved cognition ( Diagnostic and Statistical Manual version 5, 7‐level scale, adjusted common OR, 0.64 [95% CI, 0.41–0.99]). ISMN/cilostazol versus control improved cognition ( Diagnostic and Statistical Manual version 5, 7‐level adjusted common OR, 0.40 [95% CI, 0.21–0.78]), mood (Zung adjusted mean difference, −6.94 [95% CI, −12.25 to −1.64]) and global stroke impact (Mann–Whitney difference, −0.23 [95% CI, −0.37 to −0.09]). Conclusions: A reduction in the composite outcome, cognitive impairment, dependency, and stroke impact was seen within 6 months of starting ISMN or cilostazol. Registration: URL: www.isrctn.com ; Unique Identifier: ISRCTN14911850.